R&D

Sri Krishna Pharmaceuticals Ltd (SKPL), established in 1974, started life as a pioneer in the bulk manufacture of acetaminophen (Paracetamol) for the domestic Indian market. Today, the company is a vertically integrated bulk manufacturer of multiple first-line-of-defence APIs, PFIs and finished dosage drugs. Paracetamol is still very important to the company and the company remains one of the largest manufacturers in the world.

The Indian Institute of Petroleum, one of the constituent laboratories under the umbrella of Council of Scientific & Industrial Research (CSIR), was established on September 26, 1960. The Institute has continued its efforts to grow into an internationally renowned R&D organization, providing quality research and innovative technologies for the national and international market place and to produce technical support to the industry. Accredited with ISO 9001: 2015 certificate, Institute is devoted to multidisciplinary areas of Research and Development in the downstream sector of hydrocarbon and related industry.

All-India Institute of Medical Sciences was established as an institution of national importance by an Act of Parliament with the objects to develop patterns of teaching in Undergraduate and Post-graduate Medical Education in all its branches so as to demonstrate a high standard of Medical Education in India; to bring together in one place educational facilities of the highest order for the training of personnel in all important branches of health activity; and to attain self-sufficiency in Post-graduate Medical Education.

Post : Senior Research Fellow

The PhRMA Foundation has announced two new grant-funding opportunities that will provide substantial support for young researchers with innovative projects in Drug Discovery and Drug Delivery. Funding of up to $100,000 is available, with categories including pre/postdoctoral fellowships and research starter grants. Deadline for Letters of Intent for the new grants is May 15, 2020.

The ICGEB is an international, nonprofit research organization. Established as a special project of UNIDO, it became fully autonomous in 1994 and now counts over 60 Member States. The International Centre for Genetic Engineering and Biotechnology provides a scientific and educational environment of the highest standard and conducts innovative research in life sciences for the benefit of developing countries.

Medreich is a fully integrated pharmaceutical company with an established presence across the globe. The company is involved in the CMO & CDMO business of pharmaceutical preparations in various dosage forms catering to diverse Therapeutic categories.  Medreich has an advanced state of the art Research and Development centre with proven scientific competence to develop formulations as Patent Non-infringing and Niche generics in differentiated dosage form for global regulated markets.

Across the world, countries are being challenged by the COVID-19 pandemic in ways they have never been before. Science, Engineering, and Technology will play a critical role in finding solutions to this global challenge through the development of new vaccines, devices, diagnostic tools, and information systems, as well as strategies to help communities and nations manage and deploy resources to combat this pandemic. Global challenges call for global collaborations and partnerships, bringing together the best and brightest scientists, engineers, and entrepreneurs to work together to find solutions not only to address the current pandemic, but also for the challenges that lie ahead. Collaborations and networks not only help to leverage and share expertise across S&T communities, thereby creating synergy, but often lead to the generation of innovative and transformative solutions. Collaboration, both national and international, facilitates the development of a diverse, globally-engaged science, engineering, and technology-enabled workforce.

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS. Backed by over 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Generics, Biosimilars, Custom Pharmaceutical services and Branded Generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products.